EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Comprehensive Single-Center Analysis of Subcutaneous Infliximab in the Management of Inflammatory Bowel Disease, Lahore Pakistan

Junaid Mushtaq, Sehrish Sarwar, Ibtesaam Amjad

Pakistan Journal of Gastroenterology · 2026

DOI: 10.63521/pjg.42.1.2026.77 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pakistan Journal of Gastroenterology, 2026. Verfasst von Junaid Mushtaq und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Subcutaneous infliximab (SC-IFX) offers a promising alternative to intravenous infliximab (IV-IFX) for managing moderate-to-severe inflammatory bowel disease (IBD), providing pharmacokinetic stability, patient convenience, and improved adherence. Further evidence is needed to validate its clinical efficacy, safety, and pharmacokinetic profile in real-world settings.

Objective

To evaluate the clinical efficacy, safety, and pharmacokinetics of SC-IFX in patients with Crohn’s disease (CD) and ulcerative colitis (UC).

Methods

This single-center, open-label, interventional study enrolled 190 patients with IBD (58 CD, 132 UC) aged 18–75 years with moderate-to-severe disease activity (Crohn’s Disease Activity Index [CDAI] 250–450 or Mayo score 6–12). Participants received SC-IFX with a loading dose of 240 mg at weeks 0 and 2, followed by 120 mg every other week from week 4 onward. Assessments at baseline, week 11, and week 22 included disease activity (CDAI and Mayo scores), inflammatory markers (CRP and fecal calprotectin), hematological parameters, and serum infliximab levels. Adverse events were recorded per CTCAE guidelines. Statistical analyses utilized repeated measures ANOVA and chi-square tests, with significance set at P < 0.05.

Results

Among 190 patients, clinical remission was achieved in 81.3% of CD (CDAI

Zitieren

APA

Mushtaq, J., Sarwar, S., & Amjad, I. (2026). A Comprehensive Single-Center Analysis of Subcutaneous Infliximab in the Management of Inflammatory Bowel Disease, Lahore Pakistan. Pakistan Journal of Gastroenterology. https://doi.org/10.63521/pjg.42.1.2026.77

Vancouver

Mushtaq J, Sarwar S, Amjad I. A Comprehensive Single-Center Analysis of Subcutaneous Infliximab in the Management of Inflammatory Bowel Disease, Lahore Pakistan. Pakistan Journal of Gastroenterology. 2026. doi:10.63521/pjg.42.1.2026.77

BibTeX
@article{Mushtaq2026,
  author = {Mushtaq, Junaid and Sarwar, Sehrish and Amjad, Ibtesaam},
  title = {A Comprehensive Single-Center Analysis of Subcutaneous Infliximab in the Management of Inflammatory Bowel Disease, Lahore Pakistan},
  journal = {Pakistan Journal of Gastroenterology},
  year = {2026},
  doi = {10.63521/pjg.42.1.2026.77}
}
Kostenlos starten →